Cargando…
Pipeline therapies for neovascular age related macular degeneration
Age related macular degeneration (AMD) is the most common cause of vision loss in the elderly population. Neovascular AMD comprises 10% of all cases and can lead to devastating visual loss due to choroidal neovascularization (CNV). There are various cytokine pathways involved in the formation and le...
Autores principales: | Arepalli, Sruthi, Kaiser, Peter K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485527/ https://www.ncbi.nlm.nih.gov/pubmed/34598731 http://dx.doi.org/10.1186/s40942-021-00325-5 |
Ejemplares similares
-
Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Kaiser, Stephanie M, et al.
Publicado: (2021) -
Radiation therapy for neovascular age-related macular degeneration
por: Petrarca, Robert, et al.
Publicado: (2011) -
Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006) -
Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration
por: Kaiser, Peter K.
Publicado: (2007) -
Treatment of neovascular age-related macular degeneration: Current therapies
por: Augustin, Albert J, et al.
Publicado: (2009)